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Abstract 
Objective: To investigate the impact of antithyroid antibody on pregnancy outcome fol-
lowing the in vitro fertilization and embryo transfer (IVF-ET).  
Methods: A total of 90 patients (156 cycles) positive for antithyroid antibody (ATA+ group) 
and 676 infertile women (1062 cycles) negative for antithyroid antibody (ATA- group) un-
dergoing IVF/ICSI from August 2009 to August 2010 were retrospectively analyzed. 
Results: There was no significant difference in the days of ovarian stimulation, total gonad-
otropin dose, serum E2 level of HCG day and number of oocytes retrieved between the two 
groups. The fertilization rate, implantation rate and pregnancy rate following IVF-ET were 
significantly lower in women with antithyroid antibody than in control group (64.3% vs 74.6%, 
17.8% vs 27.1% and 33.3% vs 46.7%, respectively), but the abortion rate was significantly 
higher in patients with antithyroid antibody (26.9% vs 11.8%).  
Conclusion: Patients with antithyroid antibody showed significantly lower fertilization rate, 
implantation rate and pregnancy rate and higher risk for abortion following IVF-ET when 
compared with those without antithyroid antibody. Thus, the presence of antithyroid anti-
body is detrimental for the pregnancy outcome following IVF-ET. 
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Introduction 
The presence of antithyroid antibody (ATA) is 
frequently  encountered  in  general  population  and 
approximately  1/5  of  childbearing-age  women  are 
positive  for  the  anti-thyroid  peroxidase  antibody 
(TPO-Ab) or anti-thyroglobulin antibody (TG-Ab)1,2. 
Previous research showed there were 10.5% of infer-
tility women who were positive for ATA 3. It has been 
shown that the TPO-Ab level was associated with the 
thyroid-stimulating hormone (TSH) level: 1) TPO-Ab 
positive women had significantly increase TSH level; 
2) some women with normal TSH level were found to 
be positive for TPO-Ab  4,5. The presence of ATA in 
euthyroid  women  may  be  related  to  some  fertility 
problems such as increased abortion rate and raised 
incidence  of  infertility  6.  In  recent  years,  some  re-
searchers speculated that assisted conception women 
positive for ATA had poor outcome of in vitro fertili-
zation, even they were euthyroid 3. To date, no con-
sensus has been achieved on the impact of ATA on the 
outcome of in vitro fertilization and embryo transfer 
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(IVF-ET). Whether to give adjuvant therapy to regu-
late the thyroid autoimmunity before and during IVF 
is still controversial. These issues are required to be 
investigated and clarified.  
Materials and methods  
Patients  
Patients receiving IVF/ICSI in the Center of Re-
productive Medicine of the First Affiliated Hospital, 
Sun Yat-sen University, from August 2009 to August 
2010 were recruited, and these patients were divided 
into two groups, in the ATA+  group, 90 women (a 
total of 156 cycles) were positive for TG-Ab and/or 
TPO-Ab, 676 women (a total of 1062 cycles, including 
981 embryo transfer cycles and 81 embryo cryopres-
ervation cycles) negative for TG-Ab and/or TPO-Ab 
served  as  controls. All  patients  did  not  receive  any 
adjuvant  treatment,  such  as  glucocorticoids,  antico-
agulants, or other adjuvants. Patients with other au-
toimmune  diseases,  or  positive  for  anticardiolipin 
antibody, anti-nuclear antibody, lupus anticoagulant, 
or rheumatoid factor were excluded from this study.  
IVF-ET 
Long-term  pituitary  down-regulation  was  per-
formed in all patients with the following sequential 
regimen:  gonadotropin-releasing  hormone  agonist 
(GnRH-a)/gonadotropin  (Gn)/  human  chorionic 
gonadotropin  (HCG)  for  ovarian  hyperstimulation7. 
The doses of these drugs were adjusted according to 
the  age  and  the  number  of  antral  follicles  and  sex 
hormone level at baseline. Transvaginal ultrasonog-
raphy together with detection of blood estradiol (E2) 
was used to measure the ovarian response. When at 
least 2 follicles larger than 18 mm in diameter or more 
than 3 follicles larger than 17 mm in diameter, HCG 
(5,000-10,000 IU) was intramuscularly injected on the 
same day and oocytes were collected about 36 h later. 
The  selection  of  fertilization  program  (IVF  or  ICSI) 
was based on the semen condition on the day when 
the oocytes were collected. At 3 days after oocyte col-
lection, at most 3 embryos were transferred into the 
uterine. The HCG or progesterone was administered 
from the day of oocyte collection for luteal support. 14 
days after embryo transfer, the urine and serum HCG 
was measured. Once urine and serum HCG examina-
tion  showed  positive,  the  patients  received  ultraso-
nography 2 weeks later. 
Collection of clinical information 
The  clinical  information  including  age,  body 
mass index (BMI), duration of infertility, basal serum 
levels of follicle stimulating hormone (bFSH) and lu-
teinizing hormone (bLH) were collected. During the 
IVF treatment, data including days of Gn treatment, 
total Gn dose, E2 level on the day of HCG, number of 
oocytes retrived, fertilization rate, number of availa-
ble  embryos,  number  of  embryo  for  transferring, 
pregnancy rate, implantation rate and abortion rate 
were recorded and analyzed. 
Detection of serum ATA 
Serum ATA was detected with the ARCHITECT 
Anti-TPO and ARCHITECT Anti-Tg kit (Abbott La-
boratories, Abbott Park, IL, USA). It’s a Chemilumi-
nescent  Microparticle  Immunoassay  (CMIA)  for  the 
quantitative determination of the IgG class of thyroid 
peroxidase autoantibodies and thyroglobulin antoan-
tibodies  in  human  serum  and  plasma.  The  positive 
predictive value for Anti-TPO is ≥5.61 IU/ml, and it’s 
designed  to  have  an  analytical  sensitivity  of  ≤1.0 
IU/ml, concordance of 92.6%. In addition, the positive 
predictive value for anti-Tg is ≥4.11 IU/ml, and it’s 
designed to have a limit of detection of ≤1.0 IU/ml, 
concordance of 92.7%. 
Statistical analysis  
Statistical analysis was done with SPSS version 
13.0 statistic software package. Comparisons of quan-
titative data were performed with t test or Wilcoxon 
rank  sum  test  between  two  groups,  and  those  of 
qualitative data carried out with chi square test. The 
significance level (alpha) was defined as 0.05. A value 
of P<0.05 was considered statistically significant.  
Results 
General Characteristics  
There  were  no  marked  differences  in  the  age, 
BMI, duration of infertility, bFSH and bLH between 
the two groups. (Table 1).  
 
 
 
Table 1 General characteristics and basal hormone levels 
in ATA+ and ATA- group 
Variables  ATA+ group  ATA- group  p-value 
age (year)  32.8±4.5(22～45)  32.4±4.1(22～44)  0.305 
BMI (kg/m2)  20.5±2.2  20.4±2.2  0.108 
Duration of in-
fertility (year) 
4.9±3.2(1～17)  4.6±3.2(1～19)  0.112 
Basal FSH (IU/L)  5.9±2.0  5.8±1.7  0.405 
Basal LH (IU/L)  4.1±1.9  4.2±1.5  0.166 
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Controlled Ovarian Stimulation and IVF-ET 
Outcome 
Statistical analysis showed there were no signif-
icant differences in the days of ovarian stimulation, 
total Gn dose, E2 level on the day of HCG treatment 
and number of retrieved oocytes. In the ATA+ group, 
the  fertilization  rate,  number  of  available  embryos, 
implantation rate and pregnancy rate were dramati-
cally lower but abortion rate remarkably higher than 
those in the control. (Table 2)  
 
Table 2 Comparison of COS and IVF outcome between 
ATA+ and ATA- group 
Variables  ATA+ Group   Control Group  P-value 
Stimulation 
length(days) 
11.0±1.8  10.7±1.7  0.074 
Total Gn dose(IU)  2302±864  2246±736  0.885 
E2 level on the day 
of HCG (pg/ml) 
2290±1101  2342±1173  0.716 
Number of re-
trieved oocytes 
10.9±6.1  11.8±6.9  0.166 
Fertilization Rate  64.3%(729/1134)  74.6%(8848/11856)  <0.001 
Number of availa-
ble embryos 
5.3±3.9  6.0±4.2  0.01 
Number of embryo 
transferred 
2.4±0.6  2.3±0.6  0.086 
Pregnancy Rate  33.3%(52/156)  46.7%(458/981)  0.002 
Implantation Rate  17.8%(66/370)  27.1%(611/2251)  <0.001 
Abortion Rate  26.9%(14/52)  11.8%(54/458)  0.002 
 
Discussion  
Thyroid autoimmunity and IVF outcome  
In  women  receiving  IVF-ET,  the  incidence  of 
auto-antibodies is relatively high, which may be at-
tributed to the poor IVF outcome8-10. In the present 
study, we compared the IVF outcome in ATA positive 
women  and  ATA  negative  women.  Our  results 
showed  the  fertilization  rate,  number  of  available 
embryos, implantation rate and pregnancy rate in the 
ATA positive women  were significantly lower  than 
those in ATA negative women. In a previous study, 
Kin et al also reported that the ATA positive infertile 
women had a lower pregnancy rate than ATA nega-
tive infertile women (26.3% vs 39.3%), which was at 
least partly consistent with our findings 11. However, 
in the present study we not only found the signifi-
cantly lower pregnancy rate but markedly lower fer-
tilization rate and less available embryos in patients 
with ATA, which may be due to our relatively larger 
sample size. 
In the another study, Revelli et al 3 found that 
although  there  was  no  significant  difference  in  the 
proportion of patients positive for ATA between in-
fertile women and normal fertile ones, the ATA posi-
tive infertile women had a poorer IVF outcome when 
compared with ATA negative women. However, Kim 
et  al  11  and  Revelli  et  al3  did  not  investigate  the 
mechanism underlying the association between ATA 
level and IVF outcome, which has never extensively 
studied so far.  
Other researchers also showed women receiving 
assisted reproductive technology did not have an in-
creased  incidence  of  ATA  positivity,  and  the  preg-
nancy outcome was not closely related to the ATA 12,13, 
but there are also limitations of these studies includ-
ing incomplete basic clinical information of patients 
(lack  of  patient  age,  basal  hormone  levels,  etc)  and 
small sample size, which may lead to inaccurate re-
sults.  According  to  our  findings  that  ATA  positive 
patients had low fertilization rate, implantation rate, 
and pregnancy rate and high abortion rate. Regarding 
the question how ATA could interfere with fertiliza-
tion,  embryo  development  as  well  as  implantation 
potential, our study did not resolve the problem also 
and  further  studies  should  still  be  undertaken  to 
evaluate the immunologic mechanism in this special 
group. We speculate that ATA may bind to either the 
surface of the egg and/or embryo and interfere with 
fertilization  and  subsequent  embryo  development. 
Alternatively,  the  presence  of  ATA  in  endometrial 
may exert detrimental effect on embryo implantation 
and induce early pregnancy loss. 
Thyroid autoimmunity and natural abortion  
In the present study, the ATA positive women 
had significantly higher abortion rate than ATA neg-
ative  women  did.  Previous  study  revealed  TPO-Ab 
positive women had advanced age and high BMI and 
were largely pluripara when compared with TPO-Ab 
negative women 14. There was evidence that the 22.5% 
of  women  with  natural  abortion  were  positive  for 
ATA, 19.2% of women who received ART, and which 
was found only in 14.5% of healthy women15. In ad-
dition, about 13.8% of TPO-Ab positive patients had 
increased TSH level which was only observed in 2.4% 
of TPO-Ab negative women. After adjusting the age 
and TSH, ATA positivity is still an independent risk 
factor of natural abortion 1,16. In our study, there were 
no significant differences in the age, BMI, duration of 
infertility, bFSH and bLH, which exclude the influ-
ence of age, body weight and endocrine factors on the 
results. In the present study, however, we could not 
collect TSH level for all patients, so patients with ab-
normal TSH level may be included. This is one limi-
tation of the present study.  Int. J. Med. Sci. 2012, 9 
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Our results were consistent with those reported 
recently. In euthyroid mice actively immunized with 
thyroglobulin, those positive for TG-Ab had signifi-
cantly higher abortion rate after pregnancy17. In the 
early  stage  of  pregnancy,  the  presence  of  ATA  has 
been found to be associated with increased abortion 
rate.  This  association  can  not  be  influenced  by  the 
thyroid hormone and anticardiolipin antibody  2. The 
mild thyroid dysfunction is related to increased abor-
tion  rate,  which  may  be  attributed  to  the  impaired 
regulation  of  thyroid  function  resulting  in  the  in-
creased abortion rate 18. The findings above suggest 
abnormal thyroid autoimmunity is closely related to 
the increase of abortion, but the specific mechanism is 
still  poorly  understood.  The  following  explanations 
may  involve  in  the  relationship  between  ATA  and 
pregnancy loss: 1) ATA positive women have poten-
tial mild hypothyroidism 19; 2) abnormal thyroid au-
toimmunity  may  delay  the  time  of  conception.  The 
women  with  advanced  age  have  correspondingly 
increased abortion rate, which may be a main cause of 
impaired fertility 19; (3) ATA is a marker representing 
the  activation  of  autoimmunity  which  may  be  as  a 
result  of  heredity  or  result  from  early  immune  re-
sponse leading to the rejection of embryos by mother's 
immune system 2,15; 4) ATA is a secondary biomarker 
of autoimmune disease trend, but not a real cause of 
abortion 19.  
Thyroid autoimmunity and infertility    
There is controversy on the relationship between 
thyroid  autoimmunity  and  infertility.  Analysis  of 
available studies shows the infertility due to female 
factors often involves autoimmunity, and ATA can be 
used as a marker of abnormal autoimmunity 6. The 
proportion of ATA positive women and ATA level in 
women  with  implantation  failure  and  infertility  of 
unknown  cause  are  markedly  higher  than  those  in 
controls 20. Detection of TPO-Ab in euthyroid patients 
is beneficial for the identification of patients having 
high  risk  for  hypothyroidism.  In  particularly,  in 
women  preparing  for  pregnancy  and  those  having 
high  risk  for  hypothyroidism  following  pregnancy, 
detection of TPO-Ab can be used to predict hypothy-
roidism in the early stage of pregnancy and postpar-
tum thyroid dysfunction. However, in some TPO-Ab 
positive  patients,  they  have  no  obvious  thyroid  le-
sions. Whether the different antibodies or these au-
toantibodies together with other risk factors contrib-
ute to this phenomenon is still unclear 4. There is evi-
dence that controlled ovarian stimulation (COS) has 
influence  on  the  thyroid  function,  especially  in  pa-
tients with abnormal thyroid autoimmunity. Thus, we 
recommend  the  evaluation  of  thyroid  function  and 
thyroid  autoimmunity  before  assisted  reproduction, 
especially for women with recurrent failure of IVF-ET, 
recurrent  abortion,  autoimmune  diseases  or  related 
diseases  (such  as  endometriosis).  Although  the 
changes  in  the  thyroid  function  following  COS  can 
not be used to predict pregnancy outcome, the thyroid 
function of autoimmune thryoid disease (AITD) pa-
tients  should  be  closely  monitored  after  COS  and 
during the pregnancy, and treatment should be per-
formed  if  necessary  21.  Abbassi-Ghanavati  et  al  14 
found 6% women undergoing obstetric examination 
were  positive  for  thyroid  peroxidase  antibody,  and 
they  had  three  times  higher  incidence  of  placental 
abruption than those negative for this antibody (1.0% 
vs 0.3%). However, this evidence is not strong enough 
to recommend detection of thyroid function as a rou-
tine examination during the pregnancy. Hill et al also 
proposed  that  detection  of  ATA  and  evaluation  of 
“reproductive immunology phenotype” were not of 
clinical importance for women receiving IVF-ET 22. In 
the present study, patients who were positive for ATA 
had a significantly lower fertilization rate and preg-
nancy rate and a higher abortion rate than those neg-
ative for ATA did. Thus, further studies are needed to 
explore specific treatment for women with abnormal 
thyroid  autoimmunity  to  improve  their  IVF  and 
pregnancy outcome. 
Conclusion  
The present study reveals patients with antithy-
roid antibody showed significantly lower fertilization 
rate, implantation rate and pregnancy rate and higher 
risk  for  abortion  following  IVF-ET  when  compared 
with  those  without  antithyroid  antibody.  Thus,  the 
presence of antithyroid antibody is detrimental for the 
pregnancy  outcome  following  IVF-ET,  thus  further 
studies  should  investigate  appropriate  treatment  to 
regulate immune function of ATA positive patients to 
improve IVF outcome.  
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